ramucirumab
Showing 1 - 25 of 80
Gastroesophageal Adenocarcinoma Trial (Paclitaxel, Ramucirumab, Zanidatamab)
Not yet recruiting
- Gastroesophageal Adenocarcinoma
- Paclitaxel
- +2 more
- (no location specified)
Sep 12, 2023
Gastric Adenocarcinoma, Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial in Chuo Ku (TRK-950, Ramucirumab,
Not yet recruiting
- Gastric Adenocarcinoma
- +2 more
- TRK-950
- +2 more
-
Chuo Ku, JapanOsaka International Cancer Institute
Sep 14, 2023
Gastric Cancer, Gastroesophageal Junction Adenocarcinoma Trial (Ramucirumab, Paclitaxel)
No longer available
- Gastric Cancer
- Gastroesophageal Junction Adenocarcinoma
- Ramucirumab
- Paclitaxel
- (no location specified)
Jan 17, 2023
Recurrent Head Neck Cancer, Recurrent Head and Neck Squamous Cell Carcinoma, Recurrent Head and Neck Carcinoma Trial in Saint
Not yet recruiting
- Recurrent Head and Neck Cancer
- +5 more
- Ramucirumab
- Pembrolizumab
-
Saint Louis, MissouriWashington University School of Medicine
Jul 30, 2023
Head and Neck Squamous Cell Carcinoma Trial in Saint Louis (drug, other, procedure)
Active, not recruiting
- Head and Neck Squamous Cell Carcinoma
- Ramucirumab
- +4 more
-
Saint Louis, MissouriWashington University School of Medicine
Dec 21, 2022
Non Small Cell Lung Cancer, Metastatic, Recurrent Trial in United States (Lorlatinib, Ramucirumab)
Recruiting
- Non Small Cell Lung Cancer
- +2 more
- Lorlatinib
- Ramucirumab
-
Middletown, New Jersey
- +5 more
Aug 17, 2023
Gastric Adenocarcinoma Trial in Guangzhou (Sintilimab, Ramucirumab, Cisplatin)
Active, not recruiting
- Gastric Adenocarcinoma
- Sintilimab
- +5 more
-
Guangzhou, ChinaSun Yat-sen University Cancer Center
Oct 10, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (Chemotherapy, Pembrolizumab, Ramucirumab)
Not yet recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Chemotherapy
- +2 more
- (no location specified)
Jan 9, 2023
Carcinoid Tumors Trial in Boston (Ramucirumab, Somatostatin Analog)
Active, not recruiting
- Carcinoid Tumors
- Ramucirumab
- Somatostatin Analog
-
Boston, Massachusetts
- +1 more
Apr 14, 2022
Non Small Cell Lung Cancer Trial in Philadelphia (Nivolumab, Ramucirumab)
Recruiting
- Non Small Cell Lung Cancer
- Nivolumab
- Ramucirumab
-
Philadelphia, PennsylvaniaFox Chase Cancer Center
Apr 6, 2022
Gastric Adenocarcinoma, Metastatic Adenocarcinoma of the Gastroesophageal Junction Trial in Germany (Ramucirumab, TAS 102)
Active, not recruiting
- Gastric Adenocarcinoma
- Metastatic Adenocarcinoma of the Gastroesophageal Junction
- Ramucirumab
- TAS 102
-
Frankfurt, Germany
- +4 more
Mar 2, 2022
NSCLC Trial in Philadelphia (Carboplatin, Paclitaxel, Ramucirumab)
Recruiting
- Non-small Cell Lung Cancer
- Carboplatin
- +2 more
-
Philadelphia, PennsylvaniaAbramson Cancer Center of the University of Pennsylvania
Mar 14, 2022
NSCLC Stage IB, NSCLC Stage II, NSCLC Stage ?A Trial in Kashiwa, Shinjuku-Ku (Pembrolizumab, Ramucirumab, Surgery)
Recruiting
- Non-small Cell Lung Cancer Stage IB
- +2 more
- Pembrolizumab
- +2 more
-
Kashiwa, Chiba, Japan
- +1 more
Apr 4, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, biological, drug)
Not yet recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Biospecimen Collection
- +5 more
- (no location specified)
Sep 7, 2023
Non Small Cell Lung Cancer Trial in Tampa, Houston (quaratusugene ozeplasmid, pembrolizumab, docetaxel)
Recruiting
- Non Small Cell Lung Cancer
- quaratusugene ozeplasmid
- +3 more
-
Tampa, Florida
- +2 more
Sep 12, 2022
Metastatic Non-Small Lung Cell Cancer, Recurrent Non-Small Lung Cell Cancer, Stage IV Lung Cancer AJCC v8 Trial in Atlanta
Recruiting
- Metastatic Non-Small Lung Cell Cancer
- +4 more
- Docetaxel
- +2 more
-
Atlanta, GeorgiaWinship Cancer Institute of Emory University
Oct 19, 2022
NSCLC, Non-small Cell Carcinoma, NSCLC Trial (Ramucirumab, Atezolizumab, N-803)
Withdrawn
- Non-small Cell Lung Cancer
- +3 more
- Ramucirumab
- +2 more
- (no location specified)
Oct 28, 2021
Pancreatic Cancer Trial in United States (mFOLFIRINOX, Ramucirumab, Placebo)
Active, not recruiting
- Pancreatic Cancer
- mFOLFIRINOX
- +2 more
-
Scottsdale, Arizona
- +7 more
Feb 14, 2022
Recurrent Lung Non-Small Cell Carcinoma, Stage IV Lung Cancer AJCC v8 Trial (procedure, drug, biological)
Not yet recruiting
- Recurrent Lung Non-Small Cell Carcinoma
- Stage IV Lung Cancer AJCC v8
- Biospecimen Collection
- +5 more
- (no location specified)
Nov 30, 2022
Tumors, Child, Adolescent Trial in Leiden (Ramucirumab, Cyclophosphamide, Vinorelbine)
Recruiting
- Neoplasms
- +2 more
- Ramucirumab
- +7 more
-
Leiden, NetherlandsLeids Universitair Medisch Centrum
Aug 14, 2023
Esophagus Cancer, Adenocarcinoma, Stomach Cancer, Adenocarcinoma Trial in United States (Rucaparib, Ramucirumab, Nivolumab)
Recruiting
- Esophagus Cancer, Adenocarcinoma
- Stomach Cancer, Adenocarcinoma
- Rucaparib
- +2 more
-
Chicago, Illinois
- +7 more
Jan 31, 2022
Advanced Solid Tumor Trial in Japan, United States (Ramucirumab)
Terminated
- Advanced Solid Tumor
- Ramucirumab
-
Fayetteville, Arkansas
- +4 more
Aug 31, 2021
Metastatic Esophageal Adenocarcinoma, Metastatic Gastroesophageal Junction Adenocarcinoma Trial in Dallas (Abemaciclib,
Not yet recruiting
- Metastatic Esophageal Adenocarcinoma
- Metastatic Gastroesophageal Junction Adenocarcinoma
- Abemaciclib
- Ramucirumab
-
Dallas, TexasBaylor University Medical Center, Charles A Sammons Cancer Cente
Jun 4, 2021
Stomach Tumors Trial in Milan (RAMUCIRUMAB, Paclitaxel, FOLFOX 4)
Recruiting
- Stomach Neoplasms
- RAMUCIRUMAB
- +4 more
-
Milan, ItalyMaria Di Bartolomeo
Sep 3, 2021